Hepatitis E: a neglected threat.

Abstract

Hepatitis E, responsible for explosive waterborne outbreaks and sporadic cases of acute hepatitis in developing countries, affects predominantly young adults and has a fatality rate as high as 25% in pregnant women. No effective treatment exists for hepatitis E; however, a vaccine using a baculovirus-expressed recombinant hepatitis E capsid protein was recently studied in Nepal. In this review, the progress made in hepatitis E research and the recently concluded vaccine trial of the recombinant protein vaccine are briefly discussed.

• Authors: Khin Saw Aye Myint, Robert V Gibbons
• Journal: Transactions of the Royal Society of Tropical Medicine and Hygiene (Trans R Soc Trop Med Hyg) Vol. 102 Issue 3 Pg. 211-2 (Mar 2008) ISSN: 0035-9203 [Print] England
• PMID: 17658568 (Publication Type: Journal Article, Review)

Chemical References

• Viral Hepatitis Vaccines

Topics

• Adult
• Clinical Trials as Topic
• Developing Countries
• Endemic Diseases (prevention & control)
• Female
• Hepatitis E (epidemiology, prevention & control)
• Hepatitis E virus (immunology)
• Humans
• Male
• Viral Hepatitis Vaccines (therapeutic use)